Добірка наукової літератури з теми "Fibrosis regression"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Fibrosis regression".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Fibrosis regression"
Landge, Karishma, Vineeta Ojha, KartikP Ganga, Prateek Kaushik, Pooja Sharma, Priya Jagia, Sudheer Arava, et al. "Endomyocardial fibrosis regression." Journal of the Practice of Cardiovascular Sciences 5, no. 2 (2019): 102. http://dx.doi.org/10.4103/jpcs.jpcs_7_19.
Повний текст джерелаIredale, John, and Lara Campana. "Regression of Liver Fibrosis." Seminars in Liver Disease 37, no. 01 (February 15, 2017): 001–10. http://dx.doi.org/10.1055/s-0036-1597816.
Повний текст джерелаAndrade, Zilton A. "Schistosomiasis and hepatic fibrosis regression." Acta Tropica 108, no. 2-3 (November 2008): 79–82. http://dx.doi.org/10.1016/j.actatropica.2008.04.003.
Повний текст джерелаSato, Masaaki, David M. Hwang, Zehong Guan, Jonathan C. Yeung, Masaki Anraku, Dirk Wagnetz, Shin Hirayama, Thomas K. Waddell, Mingyao Liu, and Shaf Keshavjee. "Regression of Allograft Airway Fibrosis." American Journal of Pathology 179, no. 3 (September 2011): 1287–300. http://dx.doi.org/10.1016/j.ajpath.2011.05.032.
Повний текст джерелаSaffioti, Francesca, and Massimo Pinzani. "Development and Regression of Cirrhosis." Digestive Diseases 34, no. 4 (2016): 374–81. http://dx.doi.org/10.1159/000444550.
Повний текст джерелаCaligiuri, Alessandra, Alessandra Gentilini, Mirella Pastore, Stefano Gitto, and Fabio Marra. "Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression." Cells 10, no. 10 (October 15, 2021): 2759. http://dx.doi.org/10.3390/cells10102759.
Повний текст джерелаChen, Li, David A. Brenner, and Tatiana Kisseleva. "Combatting Fibrosis: Exosome‐Based Therapies in the Regression of Liver Fibrosis." Hepatology Communications 3, no. 2 (December 13, 2018): 180–92. http://dx.doi.org/10.1002/hep4.1290.
Повний текст джерелаElsharkawy, Aisha, Reham Samir, and Mohamed El-Kassas. "Fibrosis regression following hepatitis C antiviral therapy." World Journal of Hepatology 14, no. 6 (June 27, 2022): 1120–30. http://dx.doi.org/10.4254/wjh.v14.i6.1120.
Повний текст джерелаZOIS, C. D., G. H. BALTAYIANNIS, P. KARAYIANNIS, and E. V. TSIANOS. "Systematic review: hepatic fibrosis - regression with therapy." Alimentary Pharmacology & Therapeutics 28, no. 10 (November 2008): 1175–87. http://dx.doi.org/10.1111/j.1365-2036.2008.03840.x.
Повний текст джерелаAmital, H. "Fibrosis regression induced by intravenous gammaglobulin treatment." Annals of the Rheumatic Diseases 62, no. 2 (February 1, 2003): 175–77. http://dx.doi.org/10.1136/ard.62.2.175.
Повний текст джерелаДисертації з теми "Fibrosis regression"
Fallowfield, Jonathan Andrew. "The role of matrix metalloproteinase-13 in the regression of liver fibrosis." Thesis, University of Southampton, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.443059.
Повний текст джерелаBäck, Christer Matthias [Verfasser], Uwe [Akademischer Betreuer] Conrath, and Frank [Akademischer Betreuer] Tacke. "MCP-1 dependent balance of inflammatory pathways and interplay of immune cells in the liver during injury, fibrosis and injury regression : unterschiedliche MCP-1-abhängige Entzündungsmechanismen und Interaktionen von Immunzellen in der Leber / Christer Matthias Bäck ; Uwe Conrath, Frank Tacke." Aachen : Universitätsbibliothek der RWTH Aachen, 2015. http://d-nb.info/1129787419/34.
Повний текст джерелаFonseca, Yannick de Oliveira. "Cirrose hepática e sua regressão: enfoque na capilarização sinusoidal." s.n, 2011. https://www.arca.fiocruz.br/handle/icict/4149.
Повний текст джерелаMade available in DSpace on 2012-06-20T16:52:07Z (GMT). No. of bitstreams: 1 Yannick de Oliveira Fonseca Cirrose hepática e sua regressão....pdf: 1344580 bytes, checksum: 5f11b790f3db2fcbe68c8d6ae7520132 (MD5) Previous issue date: 2011
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, Bahia, Brasil
Os achados morfológicos peculiares da cirrose hepática são representados por suas alterações vasculares, que ocorrem junto com a transformação nodular do parênquima do fígado. Essas alterações são fundamentais para explicar a fisiopatologia da cirrose. Como é sabido, o fígado é o órgão central do metabolismo intermediário; sua circulação interna permite o intercâmbio de macromoléculas que são transformadas e trocadas durante etapas bioquímicas fundamentais em todo o corpo; para tais funções, a existência de sinusóides hepáticos peculiarmente adaptados é crucial. As peculiares alterações vasculares vistas na cirrose hepática têm sido consideradas irreversíveis. O presente estudo se propôs a investigá-Ias em ratos induzidos à cirrose pelo tratamento com tetracloreto de carbono (CCI4) após intervalos de tempo seguintes à sua interrupção. As mudanças estruturais das alterações sinusoidais foram particularmente estudadas por meio de técnicas histológicas, de imunofluorescência para laminina e de microscopia eletrônica de transmissão, quatro a seis meses após a interrupção do CCI4. Durante esse tempo, os nódulos regenerativos tornaram-se progressivamente alargados, enquanto o septos relacionados a eles tornaram-se delicados e fragmentados, especialmente em amostras coletadas seis meses após a interrupção do tratamento. Nossos achados estão de acordo com a sugestão de que, após a interrupção do tratamento durante quatro a seis meses, as mudanças de capilarização sinusoidal vistas na cirrose do rato induzida pelo CCI4 tendem a reverter ao normal com o tempo, apesar da persistência da estrutura nodular do parênquima hepático, as quais estão de acordo com a sugestão de que a cirrose é funcionalmente, embora não morfologicamente, reversível.
Peculiar morphologic findings from hepatic cirrhosis are represented by its vascular changes, which runs along with the nodular transformation of the parenchyma. Such changes are fundamental to explain the physiopathology of cirrhosis. As it is well known, the liver is the central organ of intermediate metabolism. Its internal circulation allows for the exchanges of macromolecules which are transformed and exchanged during fundamental biochemical steps throughout the body; for such functions the existence of peculiarly-adapted fenestrate hepatic sinusoids is crucial. Peculiar vascular alterations seen in hepatic cirrhosis have been considered irreversible. Present study was concerned with investigating vascular changes in carbon tetrachloride (CCI4)-induced cirrhosis in rats after intervals of times following interruption of CCI4 treatment. The structural changes from sinusoidal alterations were particularly studied by means of histological, transmission electron microscopy and immunofluorescent technique for laminin, four to six months following discontinuation of CCI4 treatment. During that time the regenerative nodules were seen to become progressively enlarged while their related septa became delicate and fragmented, especially in samples taken six months after treatment discontinuation. Our findings are in keeping with the suggestion that, following interruption of treatment during four to six months, the changes of sinusoidal capillarization seen in CCl4-induced rat cirrhosis tended to revert to normal with time, in spite of the persistence of the nodular arrangement of the liver parenchyma, wich are in agreement with the suggestion that cirrhosis is functionally, although not morphologically, reversible.
Trindade, Miguel João Soares. "Elastografia hepática transitória em doentes com hepatite c crónica : influência da terapêutica na regressão da fibrose." Master's thesis, 2015. http://hdl.handle.net/10451/25947.
Повний текст джерелаIntrodução: A resposta virológica sustentada tem sido associada a um prognóstico favorável nos doentes com infecção crónica pelo VHC. Os métodos de avaliação da fibrose hepática como a biópsia hepática têm como principal desvantagem serem invasivos. Novos métodos não-invasivos como a elastografia hepática transitória são compatíveis com uma avaliação sequenciada da fibrose hepática e apresentam-se como uma ferramenta valiosa no seguimento destes doentes. Objectivo: Avaliar retrospectivamente a regressão de fibrose hepática e factores associados em doentes com infecção crónica pelo vírus hepatite C, com e sem tratamento antivírico e utilizando elastografia hepática transitória (EHT). Métodos: Foram estudados retrospectivamente doentes com infecção crónica pelo VHC e com pelo menos 2 EHT válidas (Taxa de Sucesso ≥ 60% e IQR/M ≤ 0,3). Os pontos de corte foram definidos através de 110 doentes submetidos a biópsia hepática: 5.43kPa para F≥2 (VPP 0.98; VPN 0.25); 8.18kPa para F≥3 (VPP 0.87 VPN 0.97); 10,08kPa para F=4 (VPP 0.82; VPN 0.98). Os critérios de estratificação utilizados foram os seguintes: sem tratamento (ST) / com tratamento (CT) e com resposta virológica sustentada (RVS) / sem resposta virológica sustentada (SRVS). A regressão de fibrose hepática foi avaliada em todos os doentes com EHT inicial > F2 (>5.43kPa) e definida como a passagem para um estádio inferior de fibrose segundo a classificação de Peter Scheuer. Foi utilizado o Modelo de Regressão de Cox para avaliação dos factores do hospedeiro. Foi considerado como estatisticamente significativo p-value<0.05. Resultados: Foram incluídos 149 doentes, 87 do sexo feminino, idade média 52.5 ± 9.3, distribuída por genótipos (65.7% genótipo 1; 51% 1a) e dividida em dois grupos: ST=57 (38.3%) e CT=92 (61.7%). A RVS foi atingida em 62.9% dos doentes. A mediana dos valores de EHT inicial não foi significativamente diferente entre os grupos CT vs ST (6,45 vs 5,90kPa, p-value 0,236) ou os grupos RVS vs SRVS (6,55 vs 6,35kPa, p-value 0,480). O número médio de EHT foi de 3,3 e o tempo mediano entre a EHT inicial e final foi de 51 meses. O grupo RVS apresentou idade inferior (p-value 0,010), genótipo não 1 mais frequente (p-value 0,001), RNA-VHC inferior (p-value 0,017), γ-GT inferior (p-value<0,001) e contagem de plaquetas superior (p-value 0,049) quando comparado com o grupo SRVS. A regressão foi significativamente superior no grupo RVS: aumento do número de doentes com estádio < F2 (+35,6% p-value 0,001), diminuição do valor médio de EHT (7,1±3,4kPa para 5,0±1,1kPa p-value<0,001), diminuição do valor mediano de EHT (6,55kPa para 5,55kPa p-value<0,001). O grupo RVS apresentou 71% de doentes com regressão vs 26,7% do grupo SRVS (p-value 0,002) e menor tempo mediano até à regressão quando comparado com o da população (38 meses vs 51 meses, p-value 0,045). Foram associados à regressão os seguintes factores: genótipo não 1 (HR 2,478 p-value 0,030), fosfatase alcalina (HR 0,978 p-value 0,040), valor de EHT inicial (HR 0,932 p-value 0,041) e RVS (HR 3,913 p-value 0,010). Conclusões: A regressão de fibrose hepática é um processo lento. A regressão foi mais prevalente e mais rápida no grupo com RVS. A resposta virológica foi o factor que mais influenciou a regressão da fibrose. A EHT permite um follow-up contínuo e fiável ao longo do tempo, característica relevante para avaliar um fenómeno lento como a regressão de fibrose.
Introduction: Sustained virological response has been associated with better prognosis. Former tools to address liver fibrosis were invasive. New non-invasive tools, such as liver stiffness measurements (LSM), are easier to perform sequentially and more valuable in the follow up of chronic hepatitis C patients. Objective: To assess retrospectively fibrosis regression in patients with chronic hepatitis C virus infection with and without antiviral treatment, and its associated factors using LSM. Methods: Patients with chronic HCV infection were retrospectively studied with a minimum of two valid LSM (success rate ≥ 60% and IQR/M ≤ 0.3). The cutoff values were defined by our department in 110 patients submitted to liver biopsy: 5.43kPa for F≥2 (PPV 0.98; NPV 0.25); 8.18kPa for F≥3 (PPV 0.87 NPV 0.97); 10,08kPa for F=4 (PPV 0.82; NPV 0.98). Criteria for stratification were: non treated (NT) / treated (T) and with sustained virological response (SVR) and without (N-SVR) according to the international guidelines definition. Regression of liver fibrosis was defined as transition from higher to a lower stage (Peter Scheuer classification) and was evaluated in all the patients with initial LSM ≥ F2 (5.43 kPa). A Cox Regression Model was used to analyse the regression independent associated factors. Statistical significance p-value <0.05. Results: This study included 149 patients, 87 female, mean age 52.5 ± 9.3, distributed by genotypes (GT) (65.7% GT1; 51% 1a) and divided in two groups: NT=57 (38.3%) and T= 92 (61.7%) patients. The SVR was achieved in 62.9% of the patients. The median pre-treatment LSM were not significantly different between T vs NT (6,45 vs 5,90kPa, p-value 0,236) or SVR vs N-SVR (6,55 vs 6,35kPa, p-value 0,480). The average number of LSM was 3,3 and the median time between first and last LSM was 51 months. The SVR group were younger (p-value 0,010), non 1 genotype was more prevalent (p-value 0,001), had lower viral load (p-value 0,017), lower γ-GT values (p-value<0,001) and higher platelet count (p-value 0,049), when compared against non-SVR. Fibrosis regression was significantly more observed in the SVR group: increase in the number of patients with stage
Книги з теми "Fibrosis regression"
Shimizu, Hideharu, Tomasz G. Rogula, and Philip R. Schauer. Safety and Efficacy of Bariatric Surgery in Patients with Cirrhosis. Edited by Tomasz Rogula, Philip Schauer, and Tammy Fouse. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190608347.003.0021.
Повний текст джерелаZoccali, Carmine, Davide Bolignano, and Francesca Mallamaci. Left ventricular hypertrophy in chronic kidney disease. Edited by David J. Goldsmith. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0107_update_001.
Повний текст джерелаЧастини книг з теми "Fibrosis regression"
Arthur, Michael J. P. "Mechanisms of Progression and Regression of Liver Fibrosis." In Liver Cirrhosis, 1–9. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_1.
Повний текст джерелаVilaseca, Marina, and Jordi Gracia-Sancho. "Drugs to Modify Liver Fibrosis Progression and Regression." In Portal Hypertension VII, 201–18. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08552-9_18.
Повний текст джерелаPinzani, Massimo. "Liver Fibrosis and Its Regression in the Context of Portal Hypertension." In Portal Hypertension VII, 175–82. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08552-9_16.
Повний текст джерелаHernández-Gea, Virginia. "Liver Fibrosis: What Is Reversible and What Not? How to Assess Regression?" In Portal Hypertension VI, 111–15. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-23018-4_14.
Повний текст джерелаWeiss, Jeffrey N. "Regression of Fibrosis and Reversal of Diastolic Dysfunction in HFPEF Patients Treated with Allogeneic CDCs." In Stem Cell Surgery Trials in Heart Failure and Diabetes, 21–24. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-78010-4_4.
Повний текст джерелаGuido, Maria. "Regression of Liver Fibrosis." In Practical Hepatic Pathology: a Diagnostic Approach, 671–78. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-323-42873-6.00040-8.
Повний текст джерелаArthur, Michael J. P. "Role of Tissue Inhibitors of Metalloproteinases (TIMPs) in the Progression and Regression of Liver Fibrosis." In Extracellular Matrix and the Liver, 347–59. Elsevier, 2003. http://dx.doi.org/10.1016/b978-012525251-5/50020-8.
Повний текст джерелаBhattacharyya, Swati, Wenxia Wang, Zenshiro Tamaki, Bo Shi, Anjana Yeldandi, Yasuhiro Tsukimi, Masashi Yamasaki, and John Varga. "Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis." In Prime Archives in Immunology. Vide Leaf, Hyderabad, 2020. http://dx.doi.org/10.37247/pai.1.2020.2.
Повний текст джерелаWeitzman, Elissa R., Rosemary E. Ziemnik, Quian Huang, and Sharon Levy. "Alcohol and Marijuana Use and Treatment Nonadherence Among Medically Vulnerable Youth." In Medical Risks of Marijuana, 74–81. American Academy of Pediatrics, 2017. http://dx.doi.org/10.1542/9781610022767-alcohol.
Повний текст джерелаТези доповідей конференцій з теми "Fibrosis regression"
Singh, Anuraj, Vaibhav Garg, and Praveen Kumar Sahu. "Scalable Regression Model for Pulmonary Fibrosis." In 2022 IEEE 6th Conference on Information and Communication Technology (CICT). IEEE, 2022. http://dx.doi.org/10.1109/cict56698.2022.9997907.
Повний текст джерелаJ, Prof Madhuri, Vikram Bhushan, Sai Kishore HR, Sharan Kumar G, and Shreyas J. "Prediction of Pulmonary Fibrosis Progression using CNN and Regression." In 2021 3rd International Conference on Advances in Computing, Communication Control and Networking (ICAC3N). IEEE, 2021. http://dx.doi.org/10.1109/icac3n53548.2021.9725730.
Повний текст джерелаWohlfahrt, Thomas, Simon Rauber, Markus Luber, Alina Soare, Stefanie Weber, Alexandru-Emil Matei, Chih-Wei Chen, et al. "THU0343 PU.1 INHIBITOR DB1976 CONTROLS FIBROBLAST POLARIZATION IN SYSTEMIC SCLEROSISAND LEADS TO REGRESSION OF FIBROSIS IN DIFFERENT MODELS OF ORGAN FIBROSIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7653.
Повний текст джерелаMatsuda, Kenji, Miho Ohsaki, Shigeru Katagiri, Hideto Yokoi, and Katsuhiko Takabayashi. "Application of kernel logistic regression to the prediction of liver fibrosis stages in chronic hepatitis C." In 2012 Joint 6th Intl. Conference on Soft Computing and Intelligent Systems (SCIS) and 13th Intl. Symposium on Advanced Intelligent Systems (ISIS). IEEE, 2012. http://dx.doi.org/10.1109/scis-isis.2012.6505161.
Повний текст джерелаKarpec, D., R. Rudys, L. Leonaviciene, Z. Mackiewicz, R. Bradunaite, G. Kirdaite, R. Rugiene, and A. Venalis. "AB0186 High-dose narrowband ultraviolet a1 induces the regression of dermal fibrosis in animal model of scleroderma." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.4262.
Повний текст джерелаPinheiro, Renato Serquiz Elias, Emanuelly da Costa Nobre Soares, Maria Eduarda Bezerra Figueiredo, Stella Mandu Cicco, and Anna Beatriz Graciano Zuza. "Secondary parkinsonism and normal pressure hydrocephaly because of cranioencephalic trauma: a case report." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.653.
Повний текст джерелаKlisch, Stephen M., and Jeffrey C. Lotz. "Application of a Fiber-Reinforced Continuum Theory to Multiple Deformations of the Annulus Fibrosus." In ASME 1998 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1998. http://dx.doi.org/10.1115/imece1998-0118.
Повний текст джерелаKlisch, Stephen M., and Jeffrey C. Lotz. "Application of a Special Theory of Biphasic Mixtures to Annulus Fibrosus." In ASME 1998 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1998. http://dx.doi.org/10.1115/imece1998-0127.
Повний текст джерелаGroen, Harald C., Thomas T. de Weert, Frank J. H. Gijsen, Anton F. W. van der Steen, Aad van der Lugt, and Jolanda J. Wentzel. "Plaque Ulceration Is Associated With High Stear Stress in Stenotic Carotid Bifurcations." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192614.
Повний текст джерелаMAY, DAVID, ELENA SYERKO, TIM SCHMIDT, CHRISTOPHE BINETRUY, LUISA ROCHA DA SILVA, STEPAN LOMOV, and SURESH ADVANI. "BENCHMARKING VIRTUAL PERMEABILITY PREDICTIONS OF REAL FIBROUS MICROSTRUCTURE." In Thirty-sixth Technical Conference. Destech Publications, Inc., 2021. http://dx.doi.org/10.12783/asc36/35901.
Повний текст джерела